Vaughan Nelson Investment Management L.P. Has $16.40 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Vaughan Nelson Investment Management L.P. trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 71.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,199 shares of the medical research company’s stock after selling 175,874 shares during the quarter. Vaughan Nelson Investment Management L.P.’s holdings in IQVIA were worth $16,398,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. 1832 Asset Management L.P. grew its holdings in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after buying an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new position in IQVIA in the 2nd quarter valued at $70,610,000. Impax Asset Management Group plc grew its holdings in IQVIA by 19.3% in the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after buying an additional 264,555 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after purchasing an additional 198,808 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. Truist Financial reduced their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. BTIG Research reduced their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. The Goldman Sachs Group reduced their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. TD Cowen reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $259.13.

IQVIA Price Performance

IQVIA stock opened at $192.68 on Monday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $34.97 billion, a PE ratio of 25.29, a P/E/G ratio of 1.98 and a beta of 1.51. IQVIA Holdings Inc. has a 12 month low of $189.63 and a 12 month high of $261.73. The stock has a 50-day moving average price of $226.95 and a two-hundred day moving average price of $228.24.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.